PV Watch Daily Blog
Fresh reporting, analysis, and expert insight on drug safety, regulatory developments, safety signals, inspections, AI in pharmacovigilance, and career trends.
Industry Alert: Rising Scrutiny Over Proxy Interviews, False Representation, and Intermediary Misconduct in Pharmacovigilance Hiring
A growing wave of concern is emerging across parts of the pharmaceutical and drug safety industry over alleged proxy interviews, false professional...
Why AEMS Signals a More Connected Future for Digital Pharmacovigilance
FDA says its new Adverse Event Monitoring System, or AEMS, is designed as a centralized platform not just for adverse event reports, but also for consumer...
Why MHRA’s Weekly Field Safety Notices Still Matter for Safety Monitoring
MHRA published Field Safety Notices: 9–13 March 2026 on 17 March 2026, listing device-related notices within its alerts, recalls, and safety-information...
Ramipril Recall After Packaging Error Raises Medication Mix-Up Risk
MHRA said Crescent Pharma Limited is recalling one batch of Ramipril 5 mg Capsules as a precautionary measure after a potential manufacturing error may have...
Why MHRA’s 30-Day Type II Safety Variation Route Matters
MHRA’s variations guidance says a reduced Type II procedure, shortened from 60 days to 30 days, is available for some safety-related variations when agreed...
What MHRA’s February 2026 Safety Roundup Signals for Drug Safety Teams
MHRA’s Safety Roundup: February 2026 pulls together recent medicines and device safety information, including semaglutide-associated NAION and falsified...
MHRA Highlights Very Rare NAION Risk with Semaglutide
MHRA says non-arteritic anterior ischemic optic neuropathy (NAION) has been very rarely reported with semaglutide and has updated product information for...
MHRA’s National Assessment Procedure Update: Why It Matters in 2026
MHRA’s National assessment procedure for medicines guidance was updated on 24 February 2026. The page explains the agency’s national assessment procedure for...
Why MHRA’s 30-Day Type II Safety Variation Route Matters
MHRA’s variations guidance says a reduced Type II procedure, shortened from 60 days to 30 days, is available for variations concerning safety issues when...
What MHRA’s February 2026 Safety Roundup Signals for Drug Safety Teams
MHRA’s Safety Roundup: February 2026 describes itself as a summary of the latest safety advice for medicines and medical device users. The roundup highlights...